301080 Stock Overview
Engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Acrobiosystems Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥40.98 |
52 Week High | CN¥74.00 |
52 Week Low | CN¥33.00 |
Beta | 0.69 |
1 Month Change | 11.97% |
3 Month Change | -6.12% |
1 Year Change | -35.86% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -61.41% |
Recent News & Updates
Recent updates
Shareholder Returns
301080 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -5.1% | -2.8% | 0.03% |
1Y | -35.9% | -17.5% | -10.2% |
Return vs Industry: 301080 underperformed the CN Biotechs industry which returned -17.5% over the past year.
Return vs Market: 301080 underperformed the CN Market which returned -11.3% over the past year.
Price Volatility
301080 volatility | |
---|---|
301080 Average Weekly Movement | 7.4% |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 7.2% |
10% most volatile stocks in CN Market | 10.8% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 301080 has not had significant price volatility in the past 3 months.
Volatility Over Time: 301080's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 776 | Yiding Chen | www.acrobiosystems.cn |
Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. The company has a collaboration with Diagnostic Biochips Inc for neurological drug discovery and commercialization.
Acrobiosystems Co.,Ltd. Fundamentals Summary
301080 fundamental statistics | |
---|---|
Market cap | CN¥4.91b |
Earnings (TTM) | CN¥139.22m |
Revenue (TTM) | CN¥552.79m |
35.2x
P/E Ratio8.9x
P/S RatioIs 301080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
301080 income statement (TTM) | |
---|---|
Revenue | CN¥552.79m |
Cost of Revenue | CN¥83.72m |
Gross Profit | CN¥469.07m |
Other Expenses | CN¥329.85m |
Earnings | CN¥139.22m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.16 |
Gross Margin | 84.86% |
Net Profit Margin | 25.18% |
Debt/Equity Ratio | 1.2% |
How did 301080 perform over the long term?
See historical performance and comparison